Neurizon Therapeutics has received US FDA clearance for its NUZ-001 regimen to join the HEALEY ALS Platform Trial as Regimen I, following completion of the agency’s 30-day review period. The move amends the existing Master Protocol under the Sean M. Healey & AMG Center for ALS Investigational New Drug, formally opening the door to clinical activities in the platform study.
The decision allows the company and trial organisers to begin the next operational steps, including single IRB submissions, site activations, and broader clinical start-up work ahead of patient enrollment, which is expected to begin in early 2026. NUZ-001 is being developed to target core drivers of amyotrophic lateral sclerosis, including TDP-43 protein aggregation and impaired autophagy, with preclinical and early clinical data suggesting favourable oral bioavailability and CNS penetration.
The HEALEY ALS Platform Trial is structured as a multicentre, double-blind, placebo-controlled, adaptive study designed to accelerate ALS drug development by testing multiple investigational regimens simultaneously. Shared trial infrastructure and harmonised processes across the Network of Excellence for ALS (NEALS) sites are intended to cut start-up times and deliver faster efficacy readouts, an obvious advantage in a disease area where progression is rapid and approved treatment options remain limited.
For Neurizon, FDA acceptance of the protocol amendment is a material regulatory milestone. It validates NUZ-001’s readiness for late-stage evaluation and embeds the company within one of the most closely watched ALS research platforms globally. Regulators’ willingness to accommodate additional regimens under the HEALEY framework also underlines the sector’s shift towards more adaptive clinical designs for neurodegenerative disease.
“Receiving the FDA’s clearance is a major milestone for Neurizon and a critical step in advancing NUZ-001 as a potential new treatment option for people living with ALS. The HEALEY ALS Platform Trial represents the gold standard for efficient and collaborative clinical development in this field, and we are proud to progress into the next phase of activation. We look forward to working closely with the HEALEY team as we move toward site initiations and study start-up, bringing us one step closer to addressing this significant unmet medical need,” said Dr Michael Thurn, Managing Director & CEO of Neurizon.
Professor Merit Cudkowicz, Principal Investigator for the HEALEY ALS Platform Trial and Director of the Sean M. Healey & AMG Center for ALS at Mass General Brigham, added: “We are pleased to welcome Neurizon’s NUZ-001 regimen into the HEALEY ALS Platform Trial. The HEALEY ALS Platform Trial Therapy Evaluation Committee previously selected NUZ-001 for inclusion as a new regimen. The FDA’s clearance to proceed with the NUZ-001 regimen is an important next step. We look forward to initiating clinical sites and beginning enrollment so we can evaluate the potential of NUZ-001 to benefit people with ALS.”
As Neurizon pushes toward first patient in during 2026, attention will now turn to how fast sites can be brought online under the single-IRB model, and how NUZ-001 performs alongside other regimens in a platform that is increasingly becoming a bellwether for ALS innovation.
